RBC Capital keeps bullish ratings on Eli Lilly and AEVEX
RBC Capital reiterated Outperform ratings for Eli Lilly and AEVEX, with price targets of $1500 and $26, respectively.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Newsmetry API reports that RBC Capital reiterated its Outperform rating on Eli Lilly and kept a $1500 price target. The target represents implied upside of 27.2% from the Oct. 9 close of $1179.27. The analyst note highlighted Eli Lilly’s strong position in the international obesity-treatment market, where Mounjaro has reached a 55% share. RBC Capital also cited the potential of Foundayo, continued growth in the incretin portfolio and a possible increase in company guidance.
Newsmetry API also reported that RBC Capital maintained an Outperform rating on AEVEX with a $26 price target. The target implies 77.7% upside from the Oct. 9 closing price of $14.63. The note pointed to $175 million in funded order activity during 3Q26, as well as AEVEX’s mature product portfolio, expanding production capacity and acquisition of BlackSea. RBC Capital said these factors support the company’s position in defense technology, despite concerns about future revenue from Ukraine-related contracts.
why it matters
The updates provide fresh analyst assessments of two companies from different sectors and may affect how investors view their growth prospects. The price targets are analyst estimates, not guaranteed market levels.
instruments
sources
- RBC Capital reiterates Outperform rating on Eli Lilly, $1500 price target — Newsmetry API, 12 October 2026 at 14:28 UTC
- RBC Capital maintains Outperform rating on AEVEX, $26 price target — Newsmetry API, 12 October 2026 at 14:27 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗